RNA-Based Therapeutics for the Treatment of Parkinson’s Disease

Abstract Parkinson’s disease (PD) is a progressive neurological condition characterized by degeneration of dopaminergic neurons in the substantia nigra, accompanied by α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation, ultimately leading to hallmark motor symptoms including tremors and bradykinesia. RNA-based therapeutics are an emerging avenue for the treatment of PD due to their ability to modulate gene expression and therefore address the underlying molecular mechanisms driving disease progression. These approaches may modulate gene expression in key PD cell types. RNA-based therapeutics have been used to target dopaminergic neurons to strategically downregulate α-synuclein aggregation, balance growth signaling, inhibit apoptosis, or alleviate mitochondrial stress. Some strategies work to decrease neuroinflammation through microglia targeting. Additionally, some strategies seek to regulate dopamine signaling within serotonergic neurons and striatal medium spiny neurons. In this review, we summarize diverse RNA modalities that have been leveraged to address PD pathophysiology and explore nonviral carriers that have emerged to facilitate RNA delivery into target cells. We then discuss RNA-based therapeutic targeting strategies in preclinical and clinical studies and examine the trajectory of the field as these nanomedicines are increasingly applied to the treatment of PD.

Authors

Institutions

Publication Details

Journal
ACS Nano Medicine
Published
2026-11-13
DOI
https://doi.org/10.1021/acsnanomed.6c00223
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

RNA-Based Therapeutics for the Treatment of Parkinson’s Disease

Owen S. Fenton, Eshan A. Narasipura, Rachel VanKeulen‐Miller, Paris Kiehl
3 links
ACS Nano Medicine
Parkinson's Disease Mechanisms and Treatments
article

RNA-Based Therapeutics for the Treatment of Parkinson’s Disease

Owen S. Fenton, Eshan A. Narasipura, Rachel VanKeulen‐Miller, Paris Kiehl
article en

Abstract

Abstract Parkinson’s disease (PD) is a progressive neurological condition characterized by degeneration of dopaminergic neurons in the substantia nigra, accompanied by α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation, ultimately leading to hallmark motor symptoms including tremors and bradykinesia. RNA-based therapeutics are an emerging avenue for the treatment of PD due to their ability to modulate gene expression and therefore address the underlying molecular mechanisms driving disease progression. These approaches may modulate gene expression in key PD cell types. RNA-based therapeutics have been used to target dopaminergic neurons to strategically downregulate α-synuclein aggregation, balance growth signaling, inhibit apoptosis, or alleviate mitochondrial stress. Some strategies work to decrease neuroinflammation through microglia targeting. Additionally, some strategies seek to regulate dopamine signaling within serotonergic neurons and striatal medium spiny neurons. In this review, we summarize diverse RNA modalities that have been leveraged to address PD pathophysiology and explore nonviral carriers that have emerged to facilitate RNA delivery into target cells. We then discuss RNA-based therapeutic targeting strategies in preclinical and clinical studies and examine the trajectory of the field as these nanomedicines are increasingly applied to the treatment of PD.

ACS Nano Medicine
University of North Carolina at Chapel Hill (US)
Good health and well-being
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon